Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Redburn Partners Upgrades Freeline Therapeutics to Buy

Redburn Partners analyst Robert Shore upgrades Freeline Therapeutics (NASDAQ:FRLN) from Neutral to Buy.
byBenzinga Newsdesk
January 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Redburn Partners analyst Robert Shore upgrades Freeline Therapeutics (NASDAQ:FRLN) from Neutral to Buy.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0